An Exploratory Study of MT-2990 in Patients With AAV
NCT06196905
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
5
Enrollment
INDUSTRY
Sponsor class
Conditions
Antineutrophil Cytoplasmic Antibody (ANCA) -Associated Vasculitis (AAV)
Interventions
DRUG:
MT-2990
Sponsor
Tanabe Pharma Corporation